Scientific Publications

Manuscripts are expected for all ORP approved studies. Additionally, submission of abstracts (prior to manuscript publication) for presentation are encouraged.  Please access the published manuscripts and abstracts in each disease state by clicking the links below:

Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts

 


 

NCCN ORP Manuscripts

 



Brain Cancer

Chamberlain MC, Colman H, Kim BT, Raizer J.  Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: A Prospective phase II trial.  J Neuro-Oncol  (2017). doi:10.1007/s11060-016-2241-7
http://link.springer.com/article/10.1007/s11060-016-2241-7

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER; Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma; J Neurooncol (2016). doi:10.1007/s11060-016-2332-5.
https://www.ncbi.nlm.nih.gov/pubmed/27853960

Jafari-Khouzani K, Gerstner E, Rosen B, Kalpathy-Cramer J. Upsampling dynamic contrast enhanced MRI. Proceedings - International Symposium on Biomedical Imaging. 2015 Jul 21. doi: 10.1109/ISBI.2015.7164047.
http://ieeexplore.ieee.org/abstract/document/7164047 

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER; Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma; J Neurooncol (2016). doi:10.1007/s11060-016-2332-5
https://www.ncbi.nlm.nih.gov/pubmed/27853960

Breast Cancer

Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo Lei, Damodaran S, Sun R, Moulder SL.  A Phase II Study of Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.  Invest New Drugs 2020 Sep 28. doi: 10.1007/s10637-020-00995-2. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32984932/

Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y. Folate receptor alpha targeted 89Zr-M9346A immuno-PET for image-guided intervention with mirvetuximab soravtansine in triple negative breast cancer. Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16 
https://www.ncbi.nlm.nih.gov/pubmed/31369274

Rimm DL, Han, G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L, Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research (2019) 21:72.
https://doi.org/10.1186/s13058-019-1156-6

Sachdev JC, Snider JN, Allen JW, Schwartzberg LS, Young RR, Javed AY, Smeltzer MP, Yunus F, Verrier CS, Jahanzeb, M. Neoadjuvant weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide with bevacizumab added concurrently to chemotherapy for operable triple-negative invasive breast cancer. J Cancer Allied Spec 2016; 2(1):3. 
http://journals.sfu.ca/jcas/index.php/jcas/article/view/59

Central Nervous System

Bruner JM, Louis DN, McLendon R, Rosenblum MK, Archambault WT, Most S, Tihan T. The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. J Neuropathol Exp Neurol (2017) 76 (3):189-194. DOI: https://doi.org/10.1093/jnen/nlw122.
https://academic.oup.com/jnen/article/76/3/189/3056523/The-Utility-of-Expert-Diagnosis-in-Surgical

Cholangiocarcinoma

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Subbiah V, Zinner R, Azad NS.  The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.  Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25.
https://www.ncbi.nlm.nih.gov/pubmed/28441383

Gastrointestinal Cancer

Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani NI. Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates. Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0240.2019. doi:10.1158/1535-7163.MCT-19-0240. [Epub ahead of print] PubMed PMID: 31575653.
https://www.ncbi.nlm.nih.gov/pubmed?term=%22Molecular+cancer+therapeutics%22%5BJour%5D+AND+Malhotra%5Bauthor%5D+AND+Pralatrexate&TransSchema=title&cmd=detailssearch

Burkart J, Owen D, Shah MH,  Abdel-Misih  S, Roychowdhury S,  Wesolowski R , Haraldsdottir S,  Reeser JW, Samorodnitsky E, Smith A, Konda B. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw 2018 Sep;16(9):1035-1040 doi: 10.6004/jnccn.2018.7043.  
http://www.jnccn.org/content/16/9/1035.full

Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB.  Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol. 2016 May;119(2):312-8. doi: 10.1016/j.radonc.2016.04.013. Epub 2016 Apr 19.
http://www.ncbi.nlm.nih.gov/pubmed/27106554

Petullo B, Wei L,Yereb M, Neal A, Rose J, Bekaii-Saab T, Wu C. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. J Gastrointest Oncol 2015. doi: 10.3978/ j.issn.2078-6891.2015.011   
http://www.thejgo.org/article/view/4049

Gynecologic Cancer

Kovisto CS, Parrish Santosh M, Bonala B, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backs FJ, Goodfellow J, Chamberlin HM, Leone G.  Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.  Neoplasia Volume 22, Issue 10, October 2020, Pages 484-496.  https://www.sciencedirect.com/science/article/pii/S1476558620301342

Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, whalen C, Dillon D, Matulonis US. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecologic Oncology 154(2019) 95-101.
https://doi.org/10.1016/j.ygyno.2019.05.003

Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Jul 15. doi: 10.1002/cncr.30196. [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/27421044  

Head and Neck Cancer

Mudianto T, Campbell K, Webb J, Zolkind P, Skidmore Z, Riley R, Barnell E, Ozgenc I, Giri T, Dunn G, Adkins D, Griffith M, Egloff A, Griffith O, Uppaluri R.  Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2021 Apr 15;27(8):2326-2339.  doi: 10.1158/1078-0432.CCR-19-4179.  Epub 2021 Feb 5.
https://pubmed.ncbi.nlm.nih.gov/33547198/

Swiecicki PL, Bellile E, Brummell C, Brenner JC, Worden FP.  Efficacy of axitinib in metastatic head and neck cancer using novel radiographic response criteria.  Cancer 20 October 2020.
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33226

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy With and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30698-4. doi: 10.1016/j.ijrobp.2019.04.034. [Epub ahead of print] PMID:31082494.
https://www.ncbi.nlm.nih.gov/pubmed?term=Margalit%2C+Danielle%5Bauthor%5D+AND+Afatinib&TransSchema=title&cmd=detailssearch

Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest New Drugs. 2018 Dec 19. doi: 10.1007/s10637-018-0696-4. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed?term=Investigational+New+Drugs%5BJour%5D+AND+Teknos%5Bauthor%5D&cmd=detailssearch

Dunn LA, Fury MG, Sherman EJ, Katabi N, Haque SS, Pfister DG. Phase I Study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck. 2017 Sep 30. doi: 10.1002/hed.24938. [Epub ahead of print]   2017 Oct 1 
https://www.ncbi.nlm.nih.gov/pubmed/28963790

Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, Pfister C, Haque S, Katabi N, Ho AL, Pfister DG.  A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).  Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346. 
https://www.ncbi.nlm.nih.gov/pubmed/28961834

Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LS, Wildes T,  Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS and Adkins DR.  Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial.  Clin Canc Res  Published OnLine First 9 November 9, 2016.  doi: 10.1158/1078-0432.CCR-16-1469.
http://clincancerres.aacrjournals.org/content/early/2016/11/09/1078-0432.CCR-16-1469

Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Hague S, Sima CS, Ni A, Antonescu CR, Katabi N, Pfister DG.  A phase II study of Axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.  Ann Oncol 2016.  [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/27566443

Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020. Epub 2015 Dec 17. 
http://www.oraloncology.com/article/S1368-8375(15)00398-X/pdf

Swiecicki P, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP.  A Phase Ii Study Evaluating Axitinib in Patients with Unresectable, Recurrent or Metastatic Head and Neck Cancer.  Invest New Drugs.  2015 Oct 10; 1-9. 
http://link.springer.com/article/10.1007/s10637-015-0293-8

Hematologic Cancer

Chow VA, Martin PS, Smith SD, Till BG, Graf SA, Edlefsen KL, Hannan LM, Mostaghel EA, Gopal AK.  Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.  Br Journal of Haematol, First published: 22 June 2020, doi.org/10.1111/bjh.16902.
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16902?af=R

Lampson BL, Kim HT, Davids MS, Abramson JS,  Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ,  Kipps TJ, Fein J,  Fernandes SM, Hanna JR, Fisher DC, and  Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances  2019 3:1167-1174.
https://doi.org/10.1182/bloodadvances.2018030221

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G,  Wierda WG, Keating MJ, and Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.  J Geriatr Oncol. 2019 Apr 17. pii: S1879-4068(19)30033-5. doi: 10.1016/j.jgo.2019.04.002. [Epub ahead of print].  PMID: 31005650. 
https://www.ncbi.nlm.nih.gov/pubmed/31005650

Dunn TJ, Dinner S, Price E, Coutré SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.
http://www.ncbi.nlm.nih.gov/pubmed/27040320

Hepatocellular Carcinoma

El Dika I, Capanu M, Chou JF, Harding J, Ly M, Hrabovsky A, Do R, Shia J, Millang B, Ma J, O'Reilly E, Abou-Alfa G. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med. 2020;00:1–7. https://doi. org/10.1002/cam4.3389
https://doi.org/10.1002/cam4.3389

Harding, JJ, Kelley RK, Tan B, Capanu M, Lobst, Do R, Shia J, Chou JF, Boussayoud C, Ferrere C, Muenkel KE, Yarmohammadi H, El Dika I, Khalil D, Ruiz , Rodriguez MR, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase 1b study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma.  The Oncologist on line 16 June 2020
https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2020-0521

Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y.  Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.  JCI Insight.  2019;4(15):e130116.
https://doi.org/10.1172/jci.insight.130116

Lung Cancer

Dy G, Prasad D, Kumar P, Attwood K, Adjei A.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.  J Thorac Oncol. 2021 Mar;16(3):e19-e20.  doi: 10.1016/j.jtho.2020.11.019.
https://pubmed.ncbi.nlm.nih.gov/33641724/

Neal JW, Costa D, Muzikansky A, Shrager J, Lanuti M, Huang J, Ramachandran K, Rangaschari D, Huberman M, Piotrowski Z, Kris M, Azzoli C, Sequist L, Chaft J .  Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients with Surgically Resected Stage I-III EGR-Mutant Non-Small-Cell Lung Cancer.  JCO Precision Oncology No.5(2021) 325-332.  Published online 2/2/21. DOI: 10.1200/PO.20.00301
https://ascopubs.org/doi/abs/10.1200/PO.20.00301?journalCode=po

Owen DH, Williams TM, Bertino EM, Xiaokui Mo, Webb A, Schweitzer C, Liu T, Roychowdhury S,  Timmers CD, Otterson GA  Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer 134 (2019) 167–173. 
https://doi.org/10.1016/j.lungcan.2019.06.017

Choi CYH, Wakelee HA, Neal JW, Pinder-Schenck MC, Michael Yu HH, Chang SD, Adler JR, Modlin LA, Harsh GR, Soltys SG, Vorinostat And Concurrent Stereotactic Radiosurgery For Non-Small Cell Lung Cancer Brain Metastases: A Phase I Dose Escalation Trial, International Journal of Radiation Oncology • Biology • Physics (2017), doi: 10.1016/j.ijrobp.2017.04.041.
http://www.redjournal.org/article/S0360-3016(17)30897-0/pdf

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer. JAMA Oncol. Published online March 09, 2017. doi:10.1001/jamaoncol.2017.0013
http://jamanetwork.com/journals/jamaoncology/fullarticle/2608280

Allendorf DJ, Bordoni RE, Grant SC, Saleh MN, Reddy VB, Jerome ML, Dixon PM, Miley DK, Singh KP, Robert F. Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC). Cancer Chemother Pharmacol. 2015 Nov;76(5):949-55. 
https://www.ncbi.nlm.nih.gov/pubmed/26395450

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA. Stromal Caveolin-1 Is Associated with Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer 2015. doi: 10.1016/j.cllc.2015.05.004. 
http://www.clinical-lung-cancer.com/article/S1525-7304%2815%2900122-9/abstract

Melanoma

Momtaz PJ. Harding J, Ariyan C, Coit DT, Merghoub T,  Gasmi B, You D, Viale A, Panageas K, Samoila A, Postow MA, Wolchok J,  Chapman PB.   Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.  Oncotarget,2017,Vol 8 (No, 62), pp 105000-105010.  
https://doi.org/10.18632/oncotarget.21072

Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda, S, Chapman P B, Daud A. Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma. Pigment Cell Melanoma Res.. 2017;00:1-5. https://doi.org/10.1111/pcmr.12644.
http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12644/full

Deuker M, Durban V, Phillips W, McMahon M. PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma. Cancer Discov 2015 5;143 doi: 10.1158/2159-8290.CD-14-0856. 
http://cancerdiscovery.aacrjournals.org/content/5/2/143.abstract

Johnson AS, Crandall H, Dahlman K, Kelley MC.  Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma. J Am Coll Surg. 2015 Apr;220(4):581-593.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.
http://www.pubfacts.com/detail/25797743

Neuroendocrine Tumors

Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Suffren S, Hicks K, Wilton J, Bies, R, Casucci D, Reidy-Lagunes D, Shah M.   Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors [published online ahead of print, 2020 Jun 11]. Cancer. 2020;10.1002/cncr.32994. doi:10.1002/cncr.32994
https://pubmed.ncbi.nlm.nih.gov/32525561/

Strosberg, JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland ED.  A Phase II Study of Axitinib in Advanced Neuroendocrine Tumors.  Endocrine Related Cancer (2016) 23, 411–418.
http://www.ncbi.nlm.nih.gov/pubmed/27080472

Peritoneal

Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019 Mar;83(3):589-598. doi: 10.1007/s00280-019-03767-9. 
https://www.ncbi.nlm.nih.gov/pubmed/30623229

Rectal Cancer

Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.  Clin Cancer Res. 2020 Apr 6. doi: 10.1158/1078-0432.CCR-19-4193. [Epub ahead of print].  PMID: 32253228
https://doi.org/10.1158/1078-0432.CCR-19-4193

Renal Cell Cancer

Minamimoto R, Barkhodari A, Harshman L, Srinivas S, Quon A.  Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinb FDG PET/CT in Advanced Renal Cell Carcinoma.  PLoS One April 28, 2016. doi:10.1371/journal.pone.0153321
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0153321 
Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM.   FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.  Cancer Imaging.2015, 15:15. 
http://www.cancerimagingjournal.com/content/15/1/15/

Sarcoma

Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma. Clin Cancer Res. 2017 Apr 4. pii: clincanres.0272.2017. doi: 10.1158/1078-0432.CCR-17-0272. [Epub ahead of print]..
https://www.ncbi.nlm.nih.gov/pubmed/28377484

Munhoz RR, D’Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, QIN LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas The Oncologist. November 2015   vol. 20  no. 11  1245-1246. http://theoncologist.alphamedpress.org/content/20/11/1245.full.pdf+html 

Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen SS, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.  British Journal of Cancer (2015) 112, 1644–1651. doi:10.1038/bjc.2015.126. 
http://www.nature.com/bjc/journal/v112/n10/full/bjc2015126a.html

Solid Tumors

Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Larry J, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, Phelps M,  Shah MH. A phase I trial of dabrafenib and pazopanib in BRAF mutated advanced malignancies. JCO Precision Oncology, published online May 14, 2018.
http://ascopubs.org/doi/full/10.1200/PO.17.00247

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI. Phase I Study of Pazopanib Plus TH-302 in Advanced Solid Tumors. Cancer Chemother Pharmacol (2017). doi:10.1007/s00280-017-3256-2
http://link.springer.com/article/10.1007/s00280-017-3256-2

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haquez S, DeBraganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.  A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.  Pediatr Blood Cancer 2016; 00: 1–9DOI: 10.1002/pbc.26409 (Epubl ahead of print).
https://www.ncbi.nlm.nih.gov/pubmed/28035748

Haraldsdottir S, Bertino E, Haglund K, Kaffenberger B, Shah MH. Radiation Recall Dermatitis with Concurrent Dabrafenib and Pazopanib Therapy. JAMA Dermatol 2016 May 1; 152(5):587-9. doi: 10.1001/jamadermatol.2015.5366. 
http://www.ncbi.nlm.nih.gov/pubmed/26886900

Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb;77(2):357-64.
http://www.ncbi.nlm.nih.gov/pubmed/26698868

Grem JL, Kos ME, Evande RE, Meza JL, Schwarz JK. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. Cancer. 2015 Aug 4.
http://www.ncbi.nlm.nih.gov/pubmed/?term=grem+and+pralatrexate

Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J..  Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy.    Invest New Drugs. 2015 Jun;33(3):700-9. doi: 10.1007/s10637-015-0238-2. Epub 2015 Apr 24.  
http://www.ncbi.nlm.nih.gov/pubmed/25902899

Thyroid Cancer

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 Jun 11. pii: clincanres.1881.2018. doi: 10.1158/1078-0432.CCR-18-1881. [Epub ahead of print]. PMID: 31186313. 
https://www.ncbi.nlm.nih.gov/pubmed/31186313

Owen D, Konda B, Sipos J, Liu T, Webb A, Ringel M., Timmers C, Shah MH. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer J Natl Compr Canc Netw 2019;17(5):409–413 doi: 10.6004/jnccn.2019.7292.
https://www.ncbi.nlm.nih.gov/pubmed/31085763

Sherman E,  Dunn L, Ho A, Baxi S, Ghossein R, Fury M, Haque S, Sima C, Cullen G, Fagin, J, Pfister, D.   Phase II Study Evaluating the Combination of Sorafenib and Temsirolimus in the Treatment of Radioactive Iodine-Refractory Thyroid Cancer.  Cancer. 2017 Jun 29. doi: 10.1002/cncr.30861. [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/28662274

Chow LQ, Santana-Davila R, Pantel A, Roth M, Anderson LN, Failor A, Doot R, Mankoff D. (2017) A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. PLOS ONE 12(6): e0178325. https://doi.org/10.1371/journal.pone.0178325

 


 

NCCN ORP Abstracts

 


 

Brain Cancer

Ly I, Cardona J, Beers A, Chang K, Brown J, Reardon D, Arrillaga-Romany I, Dietrich J, Forst D, Lee E, Jordan J, Nayak L, Wen P, Batchelor T, Kalpathy-Cramer J, Gerstner E. NIMG-68. MRI Changes in Newly Diagnosed Glioblastoma Patients Treated as Part of a Phase II Trial with Bavituximab, Radiation, and Temozolomide.  Neuro-Oncology, Volume 20, Issue suppl_6, 5 November 20
https://doi.org/10.1093/neuonc/noy148.792

Dauki A, He L, Ling Y, Sekhon A, Kendra K, Cavaliere R, Welliver M, McGregor J, Wei L, Mrozek E, Olencki T, Thelen J, Prevedello D, Thoman W, Matharbootham M, Ammirati M, Coss C, Grecula J, Phelps M. Drug Quantification in Metastatic Brain Tumors in Patients Receiving Bendamustine as a Radiosensitizer for Stereotactic Radiothera.  J Clin Oncol 36, 2018 (suppl; abstr e14017).
https://meetinglibrary.asco.org/record/164019/abstract

Chamberlain MC, Colman H, Raizer JJ. Bendamustine for Anaplastic Gliomas. J Clin Oncol 34, 2016 (suppl; abstr 2051). 
Grecula JC, Sekhon A, Cavaliere R, Kendra K, Welliver M, McGregor J, Phelps M, Wei L, He L, Mrozek E, Olencki T, Thelen J, Prevedello D, Thoman W, Ammirati M. Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1 to 4 Brain Metastases From Solid Malignancies. J Natl Compr Canc Netw2016;14:604-614 (Abstract AB2016-9).  
http://www.jnccn.org/content/14/5S/604.full.pdf

Cai X, Chandra V, Ou Y, Emblem KE, Muzikansky A, Evans J, Kalpathy-Cramer J, Dietrich J, Chi AS, Wen PY, Rosen BR, Batchelor T, Gerstner ER.  Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.  J Clin Oncol 33, 2015 (suppl; abstr 2025).

Breast Cancer

HelgasonT, Damodaran S, Hess KR, Symmans WF, Moulder SL. Folate Receptor alpha (FRα) Expression in Metastatic Triple-Negative Breast Cancer (TNBC). J Natl Compr Canc Netw  (Abstract ). J Natl Compr Canc Netw Mar2019; vol 17 issue 3.5 (Abstract CLO19-036).
https://doi.org/10.6004/jnccn.2018.7115

Heo GS,Detering L, Luehmann HP, Primeau T, Shunqiang Li S, Stec J, Kian H, Lim KH, Lockhart AC, Liu Y. 89Zr-M9346A immuno-PET imaging folate receptor alpha in triple negative breast cancer for image-guided intervention with mirvetuximab Soravtansine.  J Nucl Med May 1, 2018 vol. 59 no. supplement 1 174.
http://jnm.snmjournals.org/content/59/supplement_1/174.abstract?sid=ca2dbe76-5963-4e6c-8e28-997610cbbd61 

Carcinoid Cancer 

Iyer R, Konda B, Owen D, Attwood K, Sarker S, Suffren S, Wilton J, Bies R, Reidy D, Shah, M. Multicenter Phase 2 Study of Nintedanib in Patients (pts) with Advanced Progressing Carcinoid Tumors. NANETS 2018 Symposium Abstract C-14. 
https://nanets.org/abstracts-archive/2018/886-abstract-c14/file

Iyer R, Konda B, Attwood K, Sarker S, Suffren SA, Wilton J, Bies, R, Casucci D, Reidy D, Shah M.  Title: Multicenter Phase 2 Study of Nintedanib in patients (pts) with advanced progressing carcinoid tumors.    J Clin Oncol 36, 2018 (suppl; abstr 4105).
https://nanets.net/abstracts-archive/2017/599-t04-multicenter-phase-2-study-of-nintedanib-in-patients-pts-with-advanced-progressing-carcinoid-tumors/file

Iyer R, Konda B, Owen D, Attwood K, Sarker S, Suffren S, Reidy D, Shah, M. Multicenter Phase 2 Study of Nintedanib in Patients (pts) with Advanced Progressing Carcinoid Tumors. NANETS 2017 Symposium Abstract T4. 
Cives M, Strosberg J, Campos T, Weber T, Nickerson M, Atreya CE, Venook AP, Kelley RK, Valone T, Coppola D, Bergsland EK.  A phase II study of Axitinib in advanced carcinoid tumors:  preliminary.  J Clin Oncol 33, 2015 (suppl; abstr 4100). 

Cholangiocarcinoma

Shroff RT, O'Connor A, Gallagher D, Zahurak M, Rosner GL, Ohaji C, Sartorius-Mergenthaler S, Zinner R, Azad NS;. Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): a Phase Ib study.  J Clin Oncol 33, 2015 (suppl; abstr 4072). 

Colorectal Cancer

Boland PM, Fakih M, Attwood K,  Robins M, Iyer RV, Ma WW. A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer. J Clin Oncol 35, 2017 (suppl 4S; abstract 759).
https://meetinglibrary.asco.org/record/138944/abstract

Wu CS, Williams TM, Wei L, Umar H, Mikhail S, Ciombor KK, Noonan AM, Roychowdhury S, El-Dika SS, Krishna S, Upchurch B, McCarthy ST, Arnold M, Harzman A, Abdel-Misih S, Cirocco W, Traugott A, Bekaii-Saab TS, Wuthrick EJ.  Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC).  J Clin Oncol 35, 2017 (suppl 4S; abstract 685).
http://meetinglibrary.asco.org/content/175044-195

Wu C, Williams TM, Wei L Umar H,  Savysan A,  Mikhail S, Ciombor KK, Noonan AM, Roychowdhury S,  El-Dika SS, Krishna S, Upchurch MA, Harzman A, Abdel-Misih S, Cirocco W, Bekaii-Saab TS, Wuthrick EK: Phase I study of trametinib and neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC) that harbor KRAS, BRAF, or NRAS mutations.  J Clin Oncol 34, 2016 (suppl; abstr e14126).  
http://meetinglibrary.asco.org/content/164209-176

Gastrointestinal Cancer

Gupta, M, Fountzilas C, Vijayvergia N, Attwood K, Hochster HS, Mukherjee S, Iyer R, Boland PM. A Phase II Study of Trifluridine/tipiracil, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO). Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS275

Xie H, Borad MJ,  Ahn DH, Bekaii-Saab TS, Tran NH, Jin Z, Pitot HC, Huebner LJ, Shi Q, Wessling J, Durgin LM,  Liu MC, Hogenson TL, Phillips WJ, Fernandez-Zapico M, Alberts SR, Mahipal A.  Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer. Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS594

Mukherjee S,  Assi H, Fountzilas C, Attwood K, Boland P, Iyer R, Catenacci DV,  Hatoum H.  Phase II Study of Trifluridine/Tipiracil (FTD/TPI) and Oxaliplatin as Induction Chemotherapy (IC) in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma (EGAC)Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS464

Bhave M , Kircher S, Kalyan A, Berlin J, Mulcahy M, Cohen S, Denlinger C, Chiorean E, Sahai V, Zalupski M, Rademaker A, Benson A, Nimeiri H.  A Phase I/II Study of the Combination of Temozolomide(TM) and Pazopanib (PZ) in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (PNETs) (NCT01465659). J Clin Oncol 36, 2018 (suppl; abstr 4096).
https://meetinglibrary.asco.org/record/160115/abstract

Boland P, Fakih M, Lim D, Attwood K, Tan W, Ebos J, Mastri M, Bies R, Fountzilas C, Iyer R, Ma W.  A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.J Clin Oncol 36, 2018 (suppl; abstr 3552).
https://meetinglibrary.asco.org/record/158840/abstract

Lee S, Krishnamurthi S, Miller A, Estfan B, Wang C, Frazer A, Iyer R . Correlation of overall survival (OS) in patients (pts) with inoperable hepatocellular carcinoma (iHCC) receiving tivozanib (TIVO) with baseline performance status. J Clin Oncol 36, 2018 (suppl; abstr e16122).
https://meetinglibrary.asco.org/record/164506/abstract

Lee S, Miller A, Krishnamurthi S, Estfan B, Frazer A, Wang C, Iyer I. Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. J Clin Oncol 36, 2018 (suppl 4S; abstr 364)
https://meetinglibrary.asco.org/record/156045/abstract 

Kalyan A, Kircher S, Denlinger CS, Berlin J, Mulcahy MF, Cohen SJ, Chiorean EG, Zalupski M, Benson AB, Nimeiri HS. A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET). J Clin Oncol. 33, 2015 (suppl 3; abstr TPS492).
http://meetinglibrary.asco.org/content/140499-158 

Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Guthrie K, Hochster HS.  SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.  J Clin Oncol 33, 2015 (suppl; abstr TPS4142). 
Malhotra U, Miller A, Bushunow PW, Loud P, Adjei A, Yendamuri SS, Robins M, Iyer RV, Khushalani NI. A phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer (aEGC). J Clin Oncol 33, 2015 (suppl 3; abstr 152).  
http://meetinglibrary.asco.org/content/140575-158 

Gynecologic Cancer

Cristea MC, Frankel P, Synold T, Stewart DB, Wang E, Jung A, Wilczynski S, Tran M, Konecny GE, Eng M, Kilpatrick L, Chen Y, Glaser S, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Rodriguez L, Wakabayashi M.  A Phase I Study of Mirvetuximab Soravtansine (MIRV) and Gemcitabine (G) in Patients (Pts) with selected FRα -positive solid tumors: Results in the Endometrial Cancer (EC) Cohort.  Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276
https://www.annalsofoncology.org/article/S0923-7534(20)40998-6/fulltext

Chelariu-Raicu A, Stur E, Ivan C, Coleman RL, Sood AK, Wen Y. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer. In: Proceedings of the 111th Annual Meeting of the American Association for Cancer Research; 2020 June 22-24. Philadelphia (PA): AACR; 2020. Abstract 1237/20
https://www.abstractsonline.com/pp8/#!/9045/presentation/3480

Khan R, Stets C, Demoret B, Chen JL, Hays JL. Increasing Folate Receptor Alpha Expression With Chemotherapy and Hormonal Agents Improves Activity of Mirvetuximab Soravtansine (IMGN853) in Endometrial Cancer. JNCCN (2018;16(5.5):575-673 https://jnccn.org/abstract/journals/jnccn/16/5S/article-pe-1.pdf

Hoppa E, Joseph P, Nakayamaa J, Zanottia KM, Nagela CI, Waggonera SE,  DiFeo A. Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer. Gynecologic Oncology, Volume 149, 57. 
https://doi.org/10.1016/j.ygyno.2018.04.12

Wen Y, Bartsch F, Ivan C, Sood AK. Anti-Folate Receptor Antibody Directed, Antibody-Drug Conjugate Induces Autophagy Cell Death in High-Grade Serous Ovarian Cancer. JNCCN (2018;16(5.5):575-673.
Link:  https://jnccn.org/abstract/journals/jnccn/16/5S/article-p582.pdf

Cristea MC, Frankel P,  Synold T,  Mortimer J, Stewart D, Wang E, Jung1 A, Wilczynski S, Konecny GE, Parungao D, Eng M, Kilpatrick L,  Chen YJ, Glaser S, Han E, Dellinger T, Hakim A,  Lee S, Morgan RJ, Wakabayashi M. A Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine (G) in Patients with FOLR1-positive Recurrent Epithelial Ovarian (EOC), Endometrial Cancer (EC), or Triple Negative Breast Cancer (TNBC). J Clin Oncol 37, 2019 (suppl; abstr 3009). 
https://meetinglibrary.asco.org/record/174209/abstract

Swetzig WM, Lurain JR, Berry E, Pineda MJ, Shahabi S,  Perry L, Neubauer NL, Nieves-Neira W, Schink JC,  Schiller A, Novak K, Anderson N, Burdett K,  Strohl AE, Kocherginsky M, and Matei DE. Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.  J Clin Oncol 37, 2019 (suppl; abstr 5538).
https://meetinglibrary.asco.org/record/175508/abstract

Matulonis UA, Wright A, Campos S, Konstantinopoulos P, Peralta A, MacNeill K, Morrissey S, Whalen C, Liu J. A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.  In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA) AACR; 2017. Abstract CT142/23.
http://www.abstractsonline.com/pp8/#!/4292/presentation/12459

Kumar R, Wei W, Lauffer S, Fulci G, Birrer MJ.  Harnessing IMGN853-mediated cell cytoxicity response by modulating FRα expression in ovarian cancer.  J Clin Oncol 35, 2017 (suppl; abstr e17061).
https://meetinglibrary.asco.org/record/150032/abstract
Matulonis U, Wright A, Collins S, Campos SM, Konstantinopoulos P, MacNeill K, Morrissey S, Patterson V, Whalen C, Liu J.  A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.  J Clin Oncol 33, 2015 (suppl; abstr TPS5618). 

Head and Neck Cancer

Margalit DN, Haddad RI, Tishler RB, Chau N, Schoenfeld JD, Bakst RL, Misiukiewcz K, Goguen L, Annino D, Mchugh P, Bacay A, Rath L, Groden P, Catalano PS, Rabinowits G. Safety Results of a Multi-Institutional Phase 1 Clinical Trial of Afatinib in Combination with Docetaxel and Postoperative Radiation Therapy for High-Risk Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology • Biology • Physics , Volume 99 , Issue 2 , S44. http://dx.doi.org/10.1016/j.ijrobp.2017.06.115.
http://www.redjournal.org/article/S0360-3016(17)31165-3/fulltext 

Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA,  Timmers CD, Sexton JL, Beshara M,  Nichols D, Snyder N, Devine CE, Konda B, Busaidy NL. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 35, 2017 (suppl; abstr 6022)
https://meetinglibrary.asco.org/record/145877/abstract

Teknos TN, n Old MO, Grecula JC, Agrawal A, Ozer E, Carrau R, Kang S, Rocco JW, Blaka Dj, Diavolitsis V, Baiocchi RA, Kumar B, Savvides P.  A Phase I trial of Vorinostat in Combination with Concurrent Chemoradiation Therapy in the Treatment of Advanced Stage Head and Neck Squamou Cell Carcinoma. J Clin Oncol 34, 2016 (suppl; abstr 6036). 

Uppaluri R, Winkler A, Tianziang L, Law J, Haughey B, Nussenbaum B, Paniello R, Rich, J. Diaz J, Michel L, Wildes L, Dunn G, Kallogjeri D, Zolkind P, Dehdashti F, Siegel B, Chernock R, Lewis J, Piccirillo J, Adkins D.  Biomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial.   In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA) Abstract CTO70. 
https://doi.org/10.1158/1538-7445.AM2016-CT07 

Chung CH, Kang H, Kiesss A, Quon H, Murphy B, Gilbert J .  A phase I Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV-Negative or High-Risk HPV-Positive Locally Advanced-Stage II/IVa/IVb HNSCC.  J Natl Compr Canc Netw 5.5, 2015 (Abstract AB2015-3).  
http://www.jnccn.org/content/13/5S/619.full 

Hematologic Cancer

Chow VA, Martin PS, Smiith SD, Till BG, Solomon AG, Kerstin JE, Hannan LM, Mostaghel EA, Gopal, AK.  Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide. Blood (2019) 134 (Supplement_1): 5254.
https://doi.org/10.1182/blood-2019-125462

Kambhampati S, Fakhri B, Ai W,  Kaplan LD, Tuscano J,  Wieduwilt MJ , Sudhindra A,   Hwang J, Reiner J, Martinelli M, Aoun C, Ta T , Le D, Padilla M, Crawford E, Andreadis C. A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood (2019) 134 (Supplement_1): 2828.
https://doi.org/10.1182/blood-2019-123279

Torka P; Reddy N; Kader A; Groman A; Hutson A; Mavis C; Block A; Sait S; Baysal B; Neppalli V; Tario J; Wallace P; Sundaram S; Hernandez-Ilizaliturri F. A Phase 2 Study of Ofatumumab in Combination With HYPER-CVAD/MA in Patients With Newly Diagnosed Mantle Cell Lymphoma. HemaSphere: June 2019 - Volume 3 - Issue - p 105–106
https://journals.lww.com/hemasphere/Fulltext/2019/06001/A_PHASE_2_STUDY_OF_OFATUMUMAB_IN_COMBINATION_WITH.205.aspx

Mehta-Shah N, Moskowitz A, Lunning M, Lynch P, Scheuerman M,  Minnal V, Galasso N, Kumar A, Gerecitano J, Zelenetz A, Hamlin P, Noy A, Matasar M, Palomba M,  Younes A, Schaffer W, Grewal R,  Rademakebr J, Sauter C, Dahi P, Myskowski P, Kheterpal M, Dogan A, Pulitzer M, Lubin L, Tang L, Ganesan N, Ni A, and Horwitz S. A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas. Blood  2017  130:821
https://ashpublications.org/blood/article/130/Supplement%201/821/83560/A-Phase-Ib-IIa-Trial-of-the-Combination-of

Yu L, Kim HT, Kasar SN, Benien P, Du W, Hoang K, Aw A, Tesar B, Improgo R, Fernandes SM, Radhakrishnan S, Klitgaard JL, Lee C, Getz G, Setlur SR and Brown JR. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation In: DOI: 10.1158/1078-0432.CCR-16-0594 Published 3 January 2017.
http://clincancerres.aacrjournals.org/content/early/2017/01/02/1078-0432.CCR-16-0594

Davids MS, Kim HT, Fernandes SM, Hellman J, Francoeur K, Arnason JE, Jacobsen E, LaCasce AS, Fisher DC, Brown JR. A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. Blood. Dec 2015, 126 (23) 4159.
http://www.bloodjournal.org/content/126/23/4159?sso-checked=true

Lundin J, Rosen ST, Österborg A, Frankfurt O, Winter JN, Rademaker S, Jennifer Kreutzer J, Bacon E, Sönnert-Husa S, Ma S. A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update. Blood. Dec 2015. 126 (23) 1734.
http://www.bloodjournal.org/content/126/23/1734?sso-checked=true

Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A, Gerecitano JF, Zelenetz AD, Hamlin Jr. PA, Noy A, Matasar MJ, Lia Palomba M, Younes A, Schaffer W, Grewal R, Rademaker J, Sauter CS, Dahi PB, Myskowski P, Kheterpal M, Dogan A, Pulitzer M, Tang L, Ni A and Horwitz SM. A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas; Blood 2016 128:2991.
http://www.bloodjournal.org/content/128/22/2991 

Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, Wierda WG, Bprthakur G, Burger JA, Ferrajoli A. Ofatumumab as front-line treatment for patients with chronic lymphocytic leukemia that are elderly and have severe co-morbidities and/or other malignancies. In: Journal of Geriatric Oncology; Volume 7/6: Supplement 1: November 2016: ISSN 1879-4068; Page 56.
http://siog2016.elsevierdigitaledition.com/#56

Hepatocellular Carcinoma 

Harding J, Kelley R, Tan B, Iobst E, Boussayoud C, Muenkel K,  Do R, Chou J, Capanu M, Ruiz C, Lee M, Wilton Iyer R, Abou-Alfa G. Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).  J Clin Oncol 36, 2018 (suppl; abstr 4083).
https://meetinglibrary.asco.org/record/160161/abstract

Harding JJ, Kelley RK, Tan B, Uhlitskykh K, Purcell C, Muenkel KE, Do RK, Capanu M, Ruiz C, Rodriguez-Lee M, Wilton j, Kuhn P, Shia J, Iyer R, Abou-Alfa G. Interim Analysis of a Phase I Study of Enzalutamide in Patients with Advanced Hepatocellular Carcinoma.  J Natl Compr Canc Netw2017;14:657-670 (Abstract AB2017-8). 
http://www.jnccn.org/content/15/5S/657.full.pdf+html 

Kelley RK, Lee MR, Hwang J, Gordan JD, Nimeiri HS, Bocobo AG, Kircher SM, Kanakamedala A, Mulcahy MF, Benson AB, Kuhn P,  Venook AP.  Detection of Circulating tumor cells (CTC) using a non-EpCAM-based, high definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on Phase I and II trials of sorafenib plus temsirolimus.    J Clin Oncol 35, 2017 (suppl 4S; abstr 311).
http://meetinglibrary.asco.org/content/177280-195

Kalathil SG, Miller A, Iyer R, Thanavala Y. Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in Hepatocellular Carcinoma. J Natl Compr Canc Netw2016;14:e-1-e-30 (Abstract AB2016-30).
http://www.jnccn.org/content/14/5S/e-1.full.pdf+html 

Connell LC, Capanu M, Do RKG, Ly M, Pinheiro N, Chou JF, Salmon K, Harding JJ, Saltz LB, Abou-Alfa, GK. Interim Results of a Phase II Trial of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma Who Progressed on Sorafenib Monotherapy (NCT01840592). J Natl Compr Canc Netw2016;14:604-614 (Abstract AB2016-8). 
http://www.jnccn.org/content/14/5S/604.full.pdf 

Kelley RK, Gordan JD, Evason K, Bracci PM, Joseph NM, Bocobo AG, Rosenthal BK, Nimeiri HS, Venook AP.  Next-generation sequencing (NGS) in an advanced hepatocellular carcinoma (HCC) cohort:  Analyses of TP53 and CTNNB1.  J Clin Oncol 34, 2016 (suppl 4S; abstr 286).
http://meetinglibrary.asco.org/content/160277-173 

Abou-Alfa G, Capanu M, Do R, Hollywood E, Ly M, Chou J, Lee J, Connell L, Wan P, Bradley M, Harding J, Saltz L.  First stage results of a second line phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib (S).  J Clin Oncol. 33, 2015 (suppl; abstr e15147).  
http://meetinglibrary.asco.org/content/149099-156

Kelley RK, Nimeiri HS, Gordan JD, Hwang J, McWhirter RM, Kanakamedala A, Atreya CE, Kulik L, Kircher S, Mulcahy MF, Benson AB, Venook AP. Phase II trial of temsiroliums (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC).  J Clin Oncol 33, 2015 (suppl 3; abstr TPS501). 
http://meetinglibrary.asco.org/content/140201-158

Lung Cancer 

Bodor JB, Patel JD, Ross EA, Litwin S, Clapper M, Levy BP, Wakelee HA, Borghaei H, Treat J: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked. J Clin Oncol 38: 2020
https://meetinglibrary.asco.org/record/191802/abstract 

Waqar SN, Rawat U, Morgensztern D, Shah S, Ward JP, Devarakonda SH, Rearden TP, Gao F, Govindan R. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). J Clin Oncol 38: 2020 (suppl; abstr e21694). 
https://meetinglibrary.asco.org/record/185721/abstract

Chaft JE, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramchandran J, Rangachari D, Huberman M, Piotrowski Z, Kris MG, Azzoli J, Sequist L, Neal JW.  Randomized Phase II Study of Adjuvant Afatinib for 3 Months vs 2 Years in Patients with Resected Stage I-III EGFR Mutant NSCLC.  J Clin Oncol 37, 2019 (suppl; abstr 8507).
https://meetinglibrary.asco.org/record/173513/abstract

Elamin YY, Antonoff M, Blakely C, Baggstorm M, Bivona T,  Lei X, Louie AV, Doebele RC, Rusthoven C, Lee P, Govindan R, Swisher S C, Papadimitrakopoulou VA, Heymach JV, Gomez DR. 1509Tip. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy292.130.
https://doi.org/10.1093/annonc/mdy292.130

Owen DH, Bertino EM, Williams TM, Mo X, Timmers CD, Webb A, Roychowdhury S, Villalona-Calero MA, Otterson GA. AB2018-77. Mutation Analysis of a Prospective Phase II Trial of Carboplatin and Nab-Paclitaxel for Metastatic Non–Small Cell Lung Cancer. J Natl Compr Canc Netw 2018;16:e-1-e-55. http://www.jnccn.org/content/16/5S/e-1.full#sec-4 

Rimm D, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Hirsch FR, Wistuba II. A prospective, multi-institutional assessment of four assays for PD-L1 expression in NSCLC by immunohistochemistry. J Thorac Oncol. 2016 Nov;11(11):S249. DOI: 
http://dx.doi.org/10.1016/j.jtho.2016.09.006 

Dy GK, Kim ES, Baumgart MA, Mattes M, Ma PC, Gadgeel SM, Molina JR, Attwood K, Alex A. Adjei AA. A Phase II Randomized, Placebo-Controlled Trial Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC) Undergoing ChemoRadiation Therapy (CRT): A National Comprehensive Cancer Network-Sponsored Study. J Clin Oncol 34, 2016 (suppl; abstr TPS8572).  
http://abstracts.asco.org/176/AbstView_176_168388.html 

Mehra R, Turaka A, Meyer JE, Egleston BL, Tanvetyanon T, Pinder MC, Dilling TJ, Williams CC, Gray JE, Shirai K, Alpaugh RK, Riordan D, Somaiah N, Shah PC, Scott WJ, Simon GR, Borghaei H.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC) (NCT01059552).  J Clin Oncol 33, 2015 (suppl; abstr 7553).  
http://abstracts.asco.org/156/AbstView_156_152506.html 

Melanoma 

Opyrchal M, Miller A, Salerno KE, Iancu D,  Vona K, Nestico J, Lamonica D,  Adjei AA, Khushalani NI. Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma.  J Natl Compr Canc Netw 2017;15:e-1-e-31 (Abstract AB2017-55).
http://www.jnccn.org/content/15/5S/e-1.full#sec-3

Momtaz P, Harding JJ, Merghoub T, You D, Viale A, Panageas K, Postow M, Wolchok J, Chapman PB.  Adjuvant Dabrafenib (dab) in Patients (pts) with Surgically Resected Stage IIIC BRAFV600E/K Mutated Melanoma (mel).  13th International Congress, 2016 Nov 6-9; Boston, MA.
https://www.melanomacongress.com/docs/2016_abstracts.pdf

Algazi AP, Muthukumar AH, O'Brien K, Lencioni A, Tsai KK, Kadafour M, Chapman PB, Daud A.  Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma.  J Clin Oncol 33, 2015 (suppl; abstr 9068).  
http://abstracts.asco.org/156/AbstView_156_152674.html 

Mehra R, Turaka A, Meyer JE, Egleston BL, Tanvetyanon T, Pinder MC, Dilling TJ, Williams CC, Gray JE, Shirai K, Alpaugh RK, Riordan D, Somaiah N, Shah PC, Scott WJ, Simon GR, Borghae Hi.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC)  (NCT01059552).  J Clin Oncol 33, 2015 (suppl; abstr 7553).  
http://abstracts.asco.org/156/AbstView_156_152506.html 

Neuroendocrine Tumors

Nimeiri HS,  Pai SG, Chiorean EG, Rademaker A, Kircher SM, Mulcahy MF, Cohen SJ, Denlinger CS, Sahai V, Zalupski M, Berlin J, Benson AB. Safety and Efficacy of Combination of Temozolomide and Pazopanib in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET). J Clin Oncol 34, 2016 (suppl; abstr e15662).  
http://abstracts.asco.org/176/AbstView_176_170576.html

Peritoneal Cancer

Cristea MC, Synold TW, Frankel PH, Rivkin SE, Lim D, Chung VM, Chao J, Wakabayashi MT, Paz IB, Han ES, Lin P, Leong LA, Hakim A, Carroll MI, Openshaw H, Prakash N, Dellinger TH, Park MS, Morgan R.  Significant Pharmacologic Advantage (PA) of Intraperitoneal (IP) nab-Paclitaxel in Patients with Advanced Malignancies Primarily Confined to the Peritoneal Cavity.  J Clin Oncol 33, 2015 (suppl; abstr 2553).  
http://abstracts.asco.org/156/AbstView_156_152193.html

Prostate Cancer

de la Calle CM, Chang, A, Rashid G, Wong AC, Choi A, Feng FY, Gottschalk AR, Menzel PL , Carroll P, Nguyen HG.  Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer.  J Clin Oncol 38, 2020 (suppl 6; abstr 323).  
https://meetinglibrary.asco.org/record/183514/abstract

Renal Cell Cancer

Minamimoto R, Barkhodari A, Harshman L, Quon A, Srinivas S. Evaluation of FDG PET/CT measurement parameters for prediction of the prognosis after sunitinib therapy in renal cell carcinoma. J Nucl Med. May 1, 2015 vol. 56 no. supplement 3 1429. 
http://jnm.snmjournals.org/content/56/supplement_3/1429
Horn K, Yap J, Agarwal N, Morton K, Kadrmas D, Beardmore B, Butterfield R, Boucher K, Hoffman J. FDG- and FLT-PET for early measurement of response to 37.5 mg per day of sunitinib in metastatic renal cell carcinoma. J Nucl Med May 1, 2015 vol. 56 no. supplement 3 1213.  
http://jnm.snmjournals.org/content/56/supplement_3/1213.short 

Sarcoma

von Mehren M, Litwin S, Ravi V, Shuetze S, Mowa S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N. Multicenter Phase II Trial of Pazopanib (P) in Patients with Angiosarcoma (AS).  J Clin Onco 37, 2019 (suppl abstr 11039).
https://meetinglibrary.asco.org/record/174703/abstract

Thyroid Cancer

Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA, Timmers CD, Sexton JL, Beshara M, Nichols D, Snyder N, Devine CE, Konda B, Busaidy NL.  Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 35, 2017 (suppl; abstr 6022).
http://abstracts.asco.org/199/AbstView_199_187228.html 

Konda B, Nabhan F, Wei L,  Busaidy N, Wirth L, Daniels G, Jonas A, De Souza J, Timmers C, Sexton J, Beshara M, Nichols D, Snyder N, Devine C,  Shah, M.  Thyroglobulin does not correlate with response in radioactive iodine refractory (RAIR) BRAF mutated papillary thyroid cancer (PTC) treated with dabrafenib alone or in combination with trametinib.    87th Annual Meeting of the American Thyroid Association in Victoria, BC, Canada from October 18-22, 2017.  Thyroid. October 2017, 27(S1): P-1-A-106. 
https://doi.org/10.1089/thy.2017.29046.abstracts

Konda B; Shah M Wei L, Espinosa A, Busaidy, Naifa L., Wirth L, Daniels G, De Souza J, Sexton J, Beshara M, Liu T, Nichols D, Snyder N, Devine C, Timmers C.  Evaluation of BRAFV600E levels in cell free DNA (cfDNA) as a biomarker of response in BRAF V600E mutated radioactive iodine refractory (RAIR) differentiated thyroid cancer (DTC) treated with dabrafenib alone or in combination with trametinib.  87th Annual Meeting of the American Thyroid Association in Victoria, BC, Canada from October 18-22, 2017 .  Thyroid. October 2017, 27(S1): A-166-A-188.  https://doi.org/10.1089/thy.2017.29050.sc.abstracts